Clinical Trial Finder

Inclusion Criteria:

• - Subject who had osteoarthritis of knee diagnosed (according to the clinical and American College of Rheumatology Criteria) - Subject who has ≥ 34 on WOMAC function score at Screening and Baseline.

• - Subject who has knee pain ≥ 70 mm for one knee out of 100 mm on VAS (Visual Analog Scale) at Screening and Baseline.

• - Subject who has radiographic evidence of grade 3 osteoarthritis in the study knee based on the Kellgren and Lawrence radiographic criteria.

• - Subjects whose knee pain persists for at least 12 weeks (about 3 months) prior to screening and does not improve symptoms with non-operative treatment options.

• - Subject who is willing to discontinue all pain medications for osteoarthritis except rescue medication (< acetaminophen 3.25 g per day) at least 72 hours prior to screening and throughout the duration of study.

• - Subject who is willing and able to give written informed consent for participation in the study.

Exclusion Criteria:

• - Subject who has Body Mass Index (BMI) > 35 kg/m2.

• - Subject judged by the investigator to have a history of clinically significant disease.

• - Subject who has any of following clinically significant disease.

• - Autoimmune diseases.

• - Paget's disease, ochronosis, acromegaly, hemochromatosis, or Wilson's disease.

• - Genetic diseases (hyperkinesia, collagen gene abnormality, etc.) - Inflammatory joint disorders (e.g. rheumatoid inflammation) - Infectious joint disorders (e.g. septic arthritis) - Other joint disorders (e.g. gout, recurrent pseudogout, articular fracture, primary osteochondrosis, villonodular synovitis) - Subject who has any history of cancer or currently receiving treatment for a current cancer diagnosis.

• - Subject who is positive in pathogenic test (HIV, viral hepatitis, or syphilis) - Subject who has heart diseases (myocardial infarction, coronary artery bypass graft surgery, arrhythmia, or other serious heart diseases) or has history of heart diseases within 6 months prior to Screening.

• - Subject who have received any intra-articular therapy in any joint within 6 months prior to Screening, or surgery on the relevant knee including articular endoscopic procedures within 6 months prior to Screening.

• - Subject who has history of prolotherapy, or platelet rich plasma injection within 6 months prior to Screening.

• - Subject who have received long-acting hyaluronic acid injection (e.g. Synvisc-One®, etc.) within 6 months prior to Screening.

• - Subject who has history of stem cell therapy.

• - Subject who have significant lab abnormalities for the following parameters (If the value is within 10% of the listed laboratory exclusion criterion value and the value is considered not to be clinically significant by the investigator, the subject can be considered for enrollment): - Serum ALT and AST > 2 x upper limit of normal.

• - Serum creatinine out of normal range.

• - PT/INR out of normal range.

• - Hemoglobin < 10 g/dL for female subject and hemoglobin < 11 g/dL for male subject.

• - Platelets out of normal range.

• - Subject for whom the investigator judges the lipoaspiration can cause any problem.

• - Subject who has history of local anesthetic allergy.

• - Subject who has taken anti-inflammatory drugs (prescription and non-prescription NSAIDs), symptomatic slow acting drugs (glucosamine, chondroitin sulfate, diacerhein etc.), or oral steroids (prednisone etc.) within 14 days prior to Screening (however, those who undergo a 14-day wash-out period can participate.

)

• - Subject who is an active drug/alcohol abuser.

• - Pregnant or breast-feeding women, or women or men who are not using appropriate method of contraception (appropriate method includes hormones, bilateral tubal ligation, and barrier method with spermicide, and intra-uterine device for women and vasectomy and barrier method with spermicide for men; subjects should agree to use appropriate method) - Subject who is enrolled in any other clinical trials within 3 months from Screening.

- Subject who received the COVID-19 vaccines within 1 week from Visit 2 (Lipoaspiration, baseline) - Subject who the principal investigator considers inappropriate for the study due to any other reasons than those listed above

Study Procedures:

• - Visit 1 (Week -7) - Screening.

• - Visit 2 (Week -5) - Baseline and Randomization (Lipoaspiration) - Visit 3 (Week 0) - Treatment (Intra-articular injection) - Visit 4 (Week 4) - 4 weeks follow-up.

• - Visit 5 (Week 12) - 12 weeks follow-up.

• - Visit 6 (Week 24) - 24 weeks follow-up.

• - Visit 7 (Week 36) - 36 weeks follow-up.

- Visit 8 (Week 48) - 48 weeks follow-up (End of Study)

Arms

Experimental: JointStem

Autologous Adipose tissue derived Mesenchymal Stem Cells(AdMSC)

Placebo Comparator: Placebo

Normal Saline with Autologous Serum

Interventions

Drug: - JointStem

Autologous Adipose tissue derived Mesenchymal Stem Cells (AdMSC)

Other: - Placebo Control

Normal Saline with autologous Serum